Launch of automated IDS Cortisol assay

Immunodiagnostic Systems Holdings plc.

4 August 2020

Launch of automated IDS Cortisol assay - new addition to the IDS Hypertension portfolio

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, today launched the IDS Cortisol assay for use with the IDS Automated System in the European market and other countries which accept the CE mark.  

Measurement of Cortisol concentrations can be used to assist in the diagnosis and treatment of disorders of the adrenal gland, such as hypo- and hyper-cortisolism, most commonly referred to as Addison's disease and Cushing's syndrome. Many common signs of Cushing's such as obesity, high blood pressure and increased blood glucose are frequently observed in today's society. This new assay complements the existing Aldosterone, Direct Renin, ACTH and Salivary Cortisol assays in the IDS Hypertension panel, improving laboratory workflow with the IDS Automated System.

The Global market size of Cortisol testing is estimated to be approximately £8.7 million worldwide.

For further information:

Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660

Jaap Stuut, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson